When the kidneys stop filtering waste items from the blood, this is known as acute kidney damage. Body fluids, electrolytes, and acid-base balance are all affected by kidney failure. Prerenal, postrenal, and intrinsic failures can contribute to acute kidney damage. Hemodialysis and continuous renal replacement therapy may be used depending on the degree of the injury. The goal of treatment is to improve kidney function rather than totally cure the kidney.
During the forecast period, the market is expected to develop due to an increase in the frequency of acute renal injuries.
Over the projected period, the worldwide Acute Kidney Injury Treatment Market is expected to develop due to an increase in the frequency of acute kidney injuries. According to the International Society of Nephrology, acute kidney damage affects roughly 13.3 million people worldwide each year. Acute renal damage is also responsible for 1.7 million deaths worldwide each year.
During the forecast period, increasing technological improvements are expected to boost the market growth.
The development of treatments for acute kidney injury is likely to fuel the worldwide acute kidney injury treatment market growth during the forecast period, according to key players in the market. Medtronic plc, a global leader in medical technology, services, and solutions, for example, announced the commercial introduction of the Carpediem cardio-renal pediatric dialysis emergency machine in the United States in December 2020.
The Impact of Coronavirus on the Global Acute Kidney Injury Treatment Market (COVID-19) Pandemic
The COVID-19 virus has spread to over 100 nations since its outbreak in December 2019, prompting the World Health Organization to designate it as a public health emergency. According to a World Health Organization report, coronavirus (COVID-19) has infected over 235 million people worldwide as of October 7, 2021.
Players to Watch
Quark Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Astellas Pharma, Inc., Sentien Biotechnologies, Inc., Teva Pharmaceutical Industries Ltd., Asahi Kasei Medical Co., AM-Pharma B.V., Teleflex Incorporated, Cure Medical, LLC, and Angion Biomedia Corp.
0 Comments